SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

civorebrutinib

TVTX·Travere Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1b/2a (pMN study by Everest Medicines); pre-IND for Travere's planned trials
Time to market
Years away. Travere plans to file a U.S. IND by year-end 2026 and initiate late-stage studies, meaning pivotal readouts and any potential approval would be several years out, likely in the 2029-2031 timeframe if successful.
Why 3/10
The next catalyst is the U.S. IND submission planned by year-end 2026, a procedural regulatory milestone rather than a high-impact binary event. No pivotal readout or PDUFA date is scheduled within the next 12 months, and civorebrutinib is one of several pipeline programs at a company with an already-approved commercial product (FILSPARI).
Actionable Insight NEUTRAL

Travere plans to submit a U.S. IND for civorebrutinib by year-end 2026, which would enable dosing studies. Look for IND acceptance and initial Phase 2 trial initiation in 2027. Pivotal readouts are likely years away. The stock's near-term catalysts remain FILSPARI sales execution and the Phase 3 HARMONY pegtibatinase topline data (expected 2H 2027).

Price Chart

Loading chart...

Executive Summary

Civorebrutinib (also known as EVER001/XNW1011) is an investigational oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor that Travere Therapeutics in-licensed from Everest Medicines in June 2026 for $112.5 million upfront, with up to $1.03 billion in potential milestones. The drug has shown proof of concept in a Phase 1b/2a trial for primary membranous nephropathy (pMN), demonstrating rapid reductions in anti-PLA2R autoantibodies (up to 93%) and proteinuria (78%) sustained through 52 weeks. Travere plans to submit a U.S. IND by year-end 2026 and advance the drug into late-stage studies across pMN, immune-mediated FSGS, and minimal change disease. However, the program remains early-stage (pre-pivotal), and no high-impact binary catalyst is scheduled within the next 12 months; the stock's near-term value is primarily driven by the approved product FILSPARI (sparsentan), which generated $200 million in Q3 2026 sales.

How It Works

Civorebrutinib blocks an enzyme called Bruton's tyrosine kinase (BTK), which is essential for the survival and activity of B cells, a type of immune cell. By inhibiting BTK, the drug reduces the production of harmful autoantibodies that attack the kidneys in certain immune-mediated kidney diseases. Unlike some older BTK inhibitors, it binds reversibly (not permanently), which may improve safety.

Trial Status

Everest Medicines completed a Phase 1b/2a open-label trial in China for primary membranous nephropathy (pMN). Data showed up to 93% reduction in anti-PLA2R autoantibodies at week 24 and 78% reduction in proteinuria sustained through 52 weeks, with a well-tolerated safety profile. Travere in-licensed global rights (ex-China and certain East/Southeast Asian countries) in June 2026 and plans to submit a U.S. IND by year-end 2026 to enable its own dosing studies across pMN, immune-mediated FSGS, and minimal change disease (MCD).

The Two-Sided Case

▲ Bull Case5
Proof-of-concept Phase 1b/2a data in pMN showed rapid and sustained reductions in anti-PLA2R autoantibodies (up to 93%) and proteinuria (78% through 52 weeks), a strong efficacy signal for a difficult-to-treat kidney disease.
As an oral, covalent reversible BTK inhibitor, civorebrutinib may offer a better safety profile than first-generation irreversible BTK inhibitors (e.g., ibrutinib), which have off-target toxicity concerns.
The drug has 'pipeline-in-a-product' potential across multiple immune-mediated kidney diseases (pMN, FSGS, MCD) with shared underlying mechanisms, expanding the addressable market.
Travere has a proven rare-disease commercial infrastructure with FILSPARI, enabling a smooth launch if approved.
Analyst consensus on TVTX is Strong Buy (19 Buy/Strong Buy, 2 Hold, 0 Sell) with a mean price target of $75.21, implying roughly 52% upside from the recent $49.56 close.
▼ Bear Case6
Civorebrutinib is still at the pre-pivotal stage; only Phase 1b/2a data exists, and those were generated by the partner (Everest) in a Chinese patient population, which may not generalize to global populations.
The BTK inhibitor class is highly competitive with 385+ drugs in development globally, primarily for oncology; standing out in kidney disease requires dedicated, expensive Phase 2/3 trials that may fail.
Travere paid $112.5 million upfront with up to $1.03 billion in milestones, a significant financial commitment for an unapproved asset, and the company reported a $52.3 million net loss in Q3 2026.
Kidney disease trials are notoriously difficult with high placebo responses and long timelines to hard endpoints like kidney function decline or dialysis dependence.
First-generation BTK inhibitor ibrutinib has been associated with kidney toxicity (FSGS) in some oncology patients, creating a class safety question even if civorebrutinib is designed to be more selective.
No pivotal readout or PDUFA is scheduled within the next 12 months, so the drug will not drive near-term share price movement.

Upcoming Catalysts

  • U.S. IND submission planned by year-end 2026
  • Initiation of Travere-sponsored Phase 2/3 studies in pMN, FSGS, and/or MCD (expected 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Travere Therapeutics, Inc. 8-K TVTX ·Originating report

Sources · 12

Hover a chip for the title
1 travere.com2 ir.travere.com3 businesswire.com4 travere.com5 everestmedicines.com6 prnewswire.com7 fiercebiotech.com8 everestmedicines.com9 everestmedicines.com10 evopointbio.com11 sec.gov12 ir.travere.com